Fox Run Management L.L.C. acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,771 shares of the specialty pharmaceutical company’s stock, valued at approximately $220,000.
Several other institutional investors also recently bought and sold shares of JAZZ. First Hawaiian Bank increased its holdings in Jazz Pharmaceuticals by 42.2% in the fourth quarter. First Hawaiian Bank now owns 320 shares of the specialty pharmaceutical company’s stock valued at $39,000 after buying an additional 95 shares during the last quarter. Stratos Wealth Partners LTD. purchased a new position in shares of Jazz Pharmaceuticals during the third quarter worth about $106,000. Riverhead Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the third quarter worth about $113,000. Financial Enhancement Group LLC purchased a new position in shares of Jazz Pharmaceuticals during the third quarter worth about $140,000. Finally, Paloma Partners Management Co purchased a new position in shares of Jazz Pharmaceuticals during the third quarter worth about $224,000. 94.70% of the stock is currently owned by institutional investors and hedge funds.
JAZZ has been the topic of several research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $201.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, November 6th. Oppenheimer set a $180.00 price objective on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, December 23rd. BidaskClub raised Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 18th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a report on Sunday, December 23rd. Finally, Wolfe Research initiated coverage on Jazz Pharmaceuticals in a report on Friday, December 14th. They set a “peer perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $189.41.
NASDAQ:JAZZ traded up $2.52 during mid-day trading on Wednesday, reaching $124.33. The stock had a trading volume of 584,863 shares, compared to its average volume of 673,823. The company has a quick ratio of 4.16, a current ratio of 4.29 and a debt-to-equity ratio of 0.52. The company has a market cap of $7.49 billion, a P/E ratio of 13.01, a PEG ratio of 0.76 and a beta of 1.17. Jazz Pharmaceuticals PLC has a twelve month low of $113.52 and a twelve month high of $184.00.
In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 700 shares of the stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $150.00, for a total value of $105,000.00. Following the completion of the transaction, the chief financial officer now directly owns 32,068 shares of the company’s stock, valued at $4,810,200. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Seamus Mulligan bought 50,000 shares of the company’s stock in a transaction on Thursday, November 15th. The stock was bought at an average cost of $144.56 per share, with a total value of $7,228,000.00. The disclosure for this purchase can be found here. 3.90% of the stock is owned by company insiders.
WARNING: “1,771 Shares in Jazz Pharmaceuticals PLC (JAZZ) Purchased by Fox Run Management L.L.C.” was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/02/13/fox-run-management-l-l-c-purchases-shares-of-1771-jazz-pharmaceuticals-plc-jazz.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.